Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities

Publication date: 15 August 2018
Source:Molecular and Cellular Endocrinology, Volume 471
Author(s): Hillary Stires, Mary M. Heckler, Xiaoyong Fu, Zhao Li, Catherine S. Grasso, Michael J. Quist, Joseph A. Lewis, Uwe Klimach, Alan Zwart, Akanksha Mahajan, Balázs Győrffy, Luciane R. Cavalli, Rebecca B. Riggins
Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to clinical ILC that can be co-targeted along with ER to improve treatment outcomes. We show that TAM has several distinct effects on the transcriptome of LCCTam cells, that this resistant cell model has acquired copy number alterations and mutations that impinge on MAPK and metabotropic glutamate receptor (GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the growth-inhibitory actions of endocrine therapy.



https://ift.tt/2MrCo4N